Get the Stockscreener App
4.15
6.96%
0.27
After Hours:
4.01
-0.14
-3.37%
Clene Inc stock is traded at $4.15, with a volume of 41,055.
It is up +6.96% in the last 24 hours and down -22.43% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
See More
Previous Close:
$3.88
Open:
$3.94
24h Volume:
41,055
Relative Volume:
0.53
Market Cap:
$32.24M
Revenue:
$442.00K
Net Income/Loss:
$-30.46M
P/E Ratio:
-6.8033
EPS:
-0.61
Net Cash Flow:
$-27.47M
1W Performance:
+1.47%
1M Performance:
-22.43%
6M Performance:
-40.88%
1Y Performance:
-54.89%
1-Day Range:
$3.94
$4.29
1-Week Range:
$3.85
$4.59
52-Week Range:
$3.8181
$12.00
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
4.15 | 32.24M | 442.00K | -30.46M | -27.47M | -0.61 |
|
KHC
Kraft Heinz Co
|
31.93 | 38.98B | 26.13B | 1.37B | 3.00B | 2.42 |
|
GIS
General Mills Inc
|
66.23 | 36.93B | 19.80B | 2.40B | 2.78B | 4.10 |
|
K
Kellanova Co
|
81.15 | 27.75B | 12.80B | 1.01B | 927.00M | 2.50 |
|
MKC
Mccormick Co Inc
|
77.79 | 21.04B | 6.68B | 792.60M | 774.40M | 2.40 |
|
HRL
Hormel Foods Corp
|
31.92 | 17.51B | 11.98B | 780.78M | 902.87M | 1.61 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Clene (NASDAQ:CLNN) Given New $84.00 Price Target at Benchmark - Defense World
Clene shares hold Buy rating as analyst sees FDA decision impacting time to market - Investing.com
Clene (NASDAQ:CLNN) Price Target Lowered to $83.00 at Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
AWM Investment Company, Inc. Expands Stake in Clene Inc - GuruFocus.com
Clene price target lowered to $83 from $86 at Canaccord - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Clene Inc - GuruFocus.com
Certain Warrants of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2024. - Marketscreener.com
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Canaccord cuts Clene stock target, holds buy rating on FDA meeting - Investing.com UK
Clene Inc (CLNN) Q3 2024 Earnings: EPS of -$1.22 Beats Estimates, Revenue at $0.087 Million Misses Expectations - GuruFocus.com
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Clene Announces Q3 2024 Results and ALS Drug Progress - TipRanks
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights - The Manila Times
(CLNN) Technical Data - Stock Traders Daily
Clene to Meet with FDA Leadership to Discuss CNM-Au8 Biomarker for ALS Treatment - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership - Yahoo Finance
Clene Unveils Phase 3 Trial Design at NEALS - TipRanks
Clene Showcases Progress on CNM-Au8 for Neurodegenerative Diseases at Investor Conferences - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences - Yahoo Finance
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
(CLNN) Trading Report - Stock Traders Daily
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements - Yahoo Finance
Clene Secures $7.3M in Funding to Advance Neurodegenerative Disease Treatment - Vancity Buzz
Canaccord retains price target, buy rating on Clene shares post-webinar - Investing.com Canada
IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences - Yahoo Finance
Clene Inc. to Present at Two Upcoming Investor Conferences in October - Vancity Buzz
Clene to Present at Upcoming October Conferences - The Manila Times
Clene (NASDAQ: CLNN) Announces Participation At Two Upcoming Investor Conferences - Barchart
Clene (NASDAQ:CLNN) Price Target Cut to $86.00 by Analysts at Canaccord Genuity Group - Defense World
Independent Chairman of the Board of Clene Picks Up 26% More Stock - Simply Wall St
Independent Chairman of the Board of Clene David Matlin Buys 26% More Shares - Yahoo Finance
Canaccord cuts Clene stock price target, maintains Buy rating By Investing.com - Investing.com South Africa
Canaccord cuts Clene stock price target, maintains Buy rating - Investing.com
Clene Secures $7.3 Million in Funding Through Direct Offering and Private Placements - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M - Yahoo Finance
Clene Inc. director David Matlin buys $438k in company stock - Investing.com
Clene Inc. CEO purchases $47,500 in company stock - Investing.com India
Clene Inc. chief science officer purchases $97,432 in company stock By Investing.com - Investing.com Australia
Clene Inc. chief science officer purchases $97,432 in company stock - Investing.com India
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements - Yahoo Finance
Clene (CLNN) Gains Momentum In The Extended Session After Completing Investment Offering - Stocks Telegraph
Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility - The Manila Times
Clene Inc. CEO purchases $47,500 in company stock By Investing.com - Investing.com Australia
Insider Buying: Chief Science Officer Mark Mortenson Acquires Sh - GuruFocus.com
Clene Inc. Secures $7.3 Million in Funding Through Direct Offerings and Private Placements - Vancity Buzz
Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements - The Globe and Mail
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
| Etherington Robert Dee | Chief Executive Officer |
Jul 29 '24 |
Option Exercise |
3.00 |
27,320 |
81,960 |
30,149 |
| General Resonance LLC | 10% Owner |
Apr 30 '24 |
Sale |
0.42 |
13,000 |
5,416 |
15,326,712 |
| General Resonance LLC | 10% Owner |
May 01 '24 |
Sale |
0.40 |
13,000 |
5,148 |
15,313,712 |
| General Resonance LLC | 10% Owner |
Apr 24 '24 |
Sale |
0.33 |
10,000 |
3,278 |
15,349,712 |
| General Resonance LLC | 10% Owner |
Apr 09 '24 |
Sale |
0.39 |
22,500 |
8,674 |
15,428,212 |
0.16%
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):